NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
January 18, 2024 00:21 ET
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for...
NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
November 07, 2023 08:50 ET
|
NeuroSigma, Inc.
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation...
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
October 03, 2023 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical...
NeuroSigma Establishes Singapore Subsidiary
July 12, 2023 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, July 12, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (“NeuroSigma”) today announced the launch of NeuroSigma Pte, Ltd., a Singapore corporation (“NeuroSigma Singapore”), representing...
NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
March 01, 2023 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced a new option for patients and caregivers seeking a telehealth evaluation for the Monarch eTNS System®. NeuroSigma is a Los...
NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
January 31, 2023 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating...
NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
November 08, 2022 10:00 ET
|
NeuroSigma, Inc.
Trials recruiting subjects at UCLA and Seattle Children’s Hospital in the United States, and at King’s College London and the University of Southampton in the United Kingdom Trials sponsored by the...
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
October 17, 2022 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of...
NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
September 27, 2022 12:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced that the Centers for Medicare & Medicaid Services ("CMS") has confirmed...
NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
June 14, 2022 11:00 ET
|
NeuroSigma, Inc.
Double-blind randomized controlled trial will enroll up to 225 children at UCLA and Seattle Children’s Hospital NeuroSigma will provide Monarch eTNS Systems and funding for long-term follow-up ...